Compare ABR & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABR | PGEN |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2004 | N/A |
| Metric | ABR | PGEN |
|---|---|---|
| Price | $8.45 | $3.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $11.10 | $7.67 |
| AVG Volume (30 Days) | 3.3M | ★ 4.2M |
| Earning Date | 10-31-2025 | 11-13-2025 |
| Dividend Yield | ★ 13.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $552,909,000.00 | $6,309,000.00 |
| Revenue This Year | N/A | $342.78 |
| Revenue Next Year | N/A | $478.46 |
| P/E Ratio | $11.14 | ★ N/A |
| Revenue Growth | N/A | ★ 59.20 |
| 52 Week Low | $8.18 | $0.65 |
| 52 Week High | $14.55 | $5.23 |
| Indicator | ABR | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 34.05 | 52.02 |
| Support Level | $8.76 | $3.48 |
| Resistance Level | $9.30 | $3.75 |
| Average True Range (ATR) | 0.29 | 0.23 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 9.68 | 89.90 |
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment. The company is externally managed and advised by Arbor Commercial Mortgage, LLC.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.